Karaciğer Tümörlerinde Yapılan Anjiyografik Hepatik Arteryel Tedaviler Sırasında C Kollu Bilgisayarlı Tomografi Tümör ve Parankim Kan Hacminin Özgün Bir Yazılım ile Değerlendirilmesi

Abstract

The aim of this study is to determine whether the C-arm CT Blood Volume (BV) imaging of hepatic tumors performed with a new prototype software is capable of measuring the BV changes in response to the hepatic arterial treatments and to validate these quantitative measurements with commercially available multi-detector computerized tomography (MDCT) perfusion software. This study was approved by the university institutional review board. 74 C-armCT BV studies with a prototype software(Siemens Healthcare,Germany) were obtained in both pre and post embolization settings(21 radioembolization-RE- plus 3 work-up angiography for RE,and 13 transarterial chemoembolization-TACE-)in total of 34 patients with hepatic tumors.C-armCT BV acquisition was performed before and after each embolization.Ten out of the 34 patients underwent MDCT perfusion study(Syngo VPCT body,Siemens) before embolization. The mean BV of 14 tumor lesions in 10 patients on MDCT perfusion was highly correlated with the BV values on C arm CT (r=0.97,p<0.01). The `BV? values obtained by C-arm CT decreased from 140.6±28.3ml/1000ml to 45.9±23.5ml/1000ml after TACE (66.37% reduction) and from 175.6±29.4ml/1000ml to 84.1±22.5ml/1000ml after RE (53.75% reduction) therapy. Quantitative BV measurement with C arm CT is well correlated with MDCT BV measurements, thus validated, and a promising tool in monitoring perfusion changes during hepatic arterial embolizations.